| Overview |
| bsm-70007M |
| Alpha Actinin 4 Antibody |
| WB, IHC |
| Specific for endogenous levels of the ~105 kDa α-actinin 4 protein. |
| Human, Mouse |
| Specifications |
| Unconjugated |
| Mouse |
| Fusion protein from the central rod domain of human α-actinin 4. |
| Monoclonal |
| 93 |
| IgG |
| Lot Dependent |
| Purified by Protein G. |
| 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol. |
| Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
| Target |
| O43707 |
| actinin 4 antibody, Actinin alpha 4 antibody, actinin4 antibody, ACTN 4 antibody, ACTN4 antibody, ACTN4_HUMAN antibody, alpha Actinin 4 antibody, Alpha-actinin-4 antibody, DKFZp686K23158 antibody, F actin cross linking protein antibody, F-actin cross-linking protein antibody, Focal segmental glomerulosclerosis 1 antibody, FSGS 1 antibody, FSGS antibody, FSGS1 antibody, Non muscle alpha actinin 4 antibody, Non-muscle alpha-actinin 4 antibody |
| α-actinin-4 is a member of the actinin protein family comprised of an actin-binding domain in the N-terminus, 4 spectrin-like repeats in the central region, and 2 EF-hand motifs in the C-terminus (Honda et al, 1998). α-actinin-4 and CLP36 form a complex in normal kidney podocytes.CLP36 is dependent on α-actinin-4 for maintenance of its level in podocytes, whereas α-actinin-4 is independent of CLP36. α-actinin-4 is widely expressed in mammalian tissues and organs, while having a high occurrence of genetic mutations in kidney podocytes (Kos et al, 2003). FSGS, focal segmental glomerulosclerosis, is a rare genetic disease that attacks the kidney's filtering units (glomeruli) causing serious scarring which leads to permanent kidney damage and even failure. Three key mutations have been found in α-actinin-4 in people diagnosed with FSGS. R310Q and Q348R, located in the spectrin-like repeats region, and K255E located in the actin-binding region. The R310Q and Q348R mutation significantly inhibits the ability of α-actinin-4 to form the complex with CLP36. The K255E mutation was reversed where it increased the ability to bind CLP36 in the actin-binding region (Liu et al, 2011). |
| Application Dilution |
| WB |
1:300-5000 |
| IHC |
|
Powered by Bioz